


REMARKS


Claims 1 to 4, 6, 8 to 10, and 13 to 20 are in the application. Claims 5, 7, 11 and 12 have been cancelled. Claims 1, 2, 3, 6, 8 and 10 have been amended. Claims 13 to 20 have been added. Support for the amendments and the newly added claims lies in the claims as originally filed, the working examples or the specification on page 4, lines 17 to 23. No new matter is believed added. Applicants reserve their right to file continuation or divisional applications on all cancelled or deleted subject matter.

The title has been amended to correct a typographical error.

The Examiner has requested an election of a single disclosed species. In response thereto, Applicants elect the compound of Example 11, Quinoxaline-5-carboxylic acid {4-[2-(1,4-dihydro-1,4-cpiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide. The compound structure of Example 11 is shown below:



In this instance, under the genus of Formula (I), R1 is hydrogen, G1 is CH=CH, Z1 is



hydrogen, G2 is a compound of formula (a), and R2 is X- Ar, wherein X is bond and Ar is a bicyclic heteroaromatic ring which is a quinoxaline ring.

A claim, claim 20 has been added to this specific compound, as have dependent claims 13 to 19 to cover a narrower genus surrounding the election of this compound. All of the claims are believed readable on this election.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



Dara L. Dinner
Agent for Applicant
Registration No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6150
Facsimile (610) 270-5090